- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05098184
Study on TIL for the Treatment of Advanced Melanoma
A Clinical Study on TIL for the Treatment of Advanced Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Clinical GC
- Phone Number: 086-18001759113
- Email: clinicaltrials@juncell.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Tenth People's Hospital
-
Contact:
- Qing Xu
- Email: xuqingmd@aliyun.com
-
Contact:
- Ling Xian Guo
- Phone Number: 086-18917681806
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 years to 75 years;
- Histologically diagnosed as primary/relapsed/metastasized melanoma;
- Expected life-span more than 3 months;
- Karnofsky≥60% or ECOG score 0-2;
- Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.
- Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;
- At least 1 evaluable tumor lesion;
Hematology and Chemistry(within 7 days prior to enrollment):
- Absolute count of white blood cells≥2.5×10^9/L;
- Absolute count of neutropils≥1.5×10^9/L;
- Absolute count of lymphocytes ≥0.7×109/L;
- Platelet count≥100×10^9;
- hemoglobin≥90 g/L;
- Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
- International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
- Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min;
- Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN);
- Totol bilirubin≤1.5×ULN;
- no absolute or relative contraindications to operation or biopsy;
- Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion;
- Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;
- Be able to understand and sign the informed consent document;
- Be able to stick to follow-up visit plan and other requirements in the agreement.
Exclusion Criteria:
- Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;
- Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;
- Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.
- Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;
- Severe physical or mental diseases;
- Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);
- Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;
- History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;
- Having received immunotherapy and developed irAE level greater than Level 3;
- Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);
- Females in pregnancy or lactation;
- History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;
- Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tumor Infiltrating Lymphocytes (TIL)
1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced melanoma after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
|
Adoptive transfer of 1x10^9-5x10^10 autologous TILs to patients i.v. in 30-120 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR)
Time Frame: Up to 36 months
|
Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1: DCR (proportion of patients) = # with CR + # with PR + # with SD / # with CR + # with PR + # with SD + # with PD.
|
Up to 36 months
|
Duration of Response (DOR)
Time Frame: Up to 36 months
|
The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1
|
Up to 36 months
|
Adverse Events (AE)
Time Frame: 6 months
|
To characterize the safety profile of GC101 TIL in patients with advanced melanoma as assessed by incidence of adverse events.
|
6 months
|
Objective Response Rate (ORR)
Time Frame: Up to 36 months
|
Proportion of patients with response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1): ORR (proportion of patients) = # with CR + # with PR / # with CR + # with PR + # with SD + # with PD. ( Except baseline evaluation within 28 days before GC101 TIL infusion,PET/CT scan will be performed at 6 weeks after TIL infusion, and than every 6 weeks for 6 months, and then every 6 months after that for up to 3 years) |
Up to 36 months
|
Progression-Free Survival (PFS)
Time Frame: Up to 36 months
|
The time length between GC101 TIL infusion and confirmed subsequent disease progression according to RECIST 1.1
|
Up to 36 months
|
Overall Survival (OS)
Time Frame: Up to 36 months
|
The length of time from the date of the start of GC101 TIL treatment that the patients are still alive
|
Up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life
Time Frame: Up to 36 months
|
Comparison of patients' quality of life before and after GC101 TIL treatment as assessed by the EORTC QLQ-30 (V3.0).
|
Up to 36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GC101-1.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment Side Effects
-
St. Martin De Porress HospitalRecruiting
-
Shanghai Juncell TherapeuticsSir Run Run Shaw HospitalRecruitingAdvanced Solid Tumor | Treatment Side Effects | Effects of Immunotherapy | Tumor Infiltrating LymphocytesChina
-
Suzhou Puhe Pharmaceutical Technology Co., LTDRecruitingTreatment Side Effects | TreatmentChina
-
Misr University for Science and TechnologyCompleted
-
Sun Yat-sen UniversityTerminatedDiarrhea | Treatment Side EffectsChina
-
Akdeniz UniversityRecruitingQuality of Life | Cancer | Treatment Side Effects | Nurse's RoleTurkey
-
Cipherome, Inc.Santa Clara Valley Medical CenterCompletedDrug-Related Side Effects and Adverse Reactions | Treatment FailureUnited States
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingBreast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of ImmunotherapyChina
-
Alexandria UniversityCompletedDrug Side Effect | Treatment Efficacy | Clinical EfficacyEgypt
-
Albert Einstein College of MedicineCompleted
Clinical Trials on Tumor Infiltrating Lymphocyte
-
CAR-T (Shanghai) Cell Biotechnology Co., Ltd.Eastern Hepatobiliary Surgery HospitalUnknown
-
Hervor TherapeuticsCancer Institute and Hospital, Chinese Academy of Medical Sciences; Women's... and other collaboratorsRecruiting
-
Grit BiotechnologyRecruitingClinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)Adult | Gynecological TumorsChina
-
XinWuRecruitingMetastatic or Recurrent Gynecological TumorsChina
-
University Hospital, Basel, SwitzerlandAnaveon AGRecruiting
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Liver Cancers | Tumor Infiltrating Lymphocyte | Advanced Pancreatic CancersChina
-
Shanghai OriginCell Therapeutics Co., Ltd.Not yet recruitingCarcinoma, Non-Small-Cell Lung
-
Henan Cancer HospitalUnknown
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Tongji Hospital; Qilu Hospital of Shandong UniversityNot yet recruitingTumor Infiltrating Lymphocytes
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina